Terms: = Leukemia AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234 AND Prognosis
34 results:
1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and molecular study of radiation-induced gliomas.
Trkova K; Sumerauer D; Bubenikova A; Krskova L; Vicha A; Koblizek M; Zamecnik J; Jurasek B; Kyncl M; Malinova B; Ondrova B; Jones DTW; Sill M; Strnadova M; Stolova L; Misove A; Benes V; Zapotocky M
Sci Rep; 2024 Feb; 14(1):3118. PubMed ID: 38326438
[TBL] [Abstract] [Full Text] [Related]
3. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by pdgfra activation due to insulator disruption in acute myeloid leukemia (AML).
Steinhäuser S; Silva P; Lenk L; Beder T; Hartmann A; Hänzelmann S; Fransecky L; Neumann M; Bastian L; Lipinski S; Richter K; Bultmann M; Hübner E; Xia S; Röllig C; Vogiatzi F; Schewe DM; Yumiceba V; Schultz K; Spielmann M; Baldus CD
Leukemia; 2023 Jan; 37(1):134-142. PubMed ID: 36411356
[TBL] [Abstract] [Full Text] [Related]
4. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve pdgfra: relevance for imatinib insensitivity.
Mueller SB; Dal Cin P; Le LP; Dias-Santagata D; Lennerz JK; Iafrate AJ; Marble HD; Brunner AM; Weinstock MJ; Luskin MR; De Angelo DJ; Stone RM; Nardi V
Blood Adv; 2022 Jan; 6(3):818-827. PubMed ID: 34587239
[TBL] [Abstract] [Full Text] [Related]
5. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract] [Full Text] [Related]
6. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract] [Full Text] [Related]
7. Update on CML-Like Disorders.
Cross NCP
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S101-S102. PubMed ID: 32862848
[TBL] [Abstract] [Full Text] [Related]
8. Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.
Gu B; Shi BY; Zhang X; Zhou SY; Chu JH; Wu XJ; Fu CC; Qiu HY; Han Y; Chen SN; Yu L; Ma X; Wu DP
Bone Marrow Transplant; 2021 Jan; 56(1):91-100. PubMed ID: 32581286
[TBL] [Abstract] [Full Text] [Related]
9. [Hypereosinophilic syndromes].
Groh M; Lefèvre G; Ackermann F; Étienne N; Kahn JE
Rev Prat; 2019 Sep; 69(7):767-773. PubMed ID: 32233322
[TBL] [Abstract] [Full Text] [Related]
10. [The 8p11 myeloproliferative syndrome: a review of recent literature].
Kirito K
Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839
[TBL] [Abstract] [Full Text] [Related]
11. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract] [Full Text] [Related]
12. Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization.
Qiu GZ; Mao XY; Ma Y; Gao XC; Wang Z; Jin MZ; Sun W; Zou YX; Lin J; Fu HL; Jin WL
Cancer Sci; 2018 Jul; 109(7):2199-2210. PubMed ID: 29788550
[TBL] [Abstract] [Full Text] [Related]
13. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract] [Full Text] [Related]
14. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract] [Full Text] [Related]
15. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract] [Full Text] [Related]
16. Long-term outcomes of imatinib in patients with FIP1L1/ pdgfra associated chronic eosinophilic leukemia: experience of a single center in China.
Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ
Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808
[TBL] [Abstract] [Full Text] [Related]
17. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract] [Full Text] [Related]
18. Hypereosinophilic Syndrome.
Curtis C; Ogbogu P
Clin Rev Allergy Immunol; 2016 Apr; 50(2):240-51. PubMed ID: 26475367
[TBL] [Abstract] [Full Text] [Related]
19. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract] [Full Text] [Related]
20. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract] [Full Text] [Related]
[Next]
